X4 Pharmaceuticals, INC 8-K filings

X4 Pharmaceuticals announced FDA approval of XOLREMDI (mavorixafor) capsules, the first drug specifically indicated for patients with WHIM syndrome.

X4 Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for a sustained period.

X4 Pharmaceuticals has released an updated corporate presentation on its website, accessible through the investor relations section.

X4 Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress towards potential FDA approval of mavorixafor for WHIM syndrome and the initiation of a Phase 3 trial for chronic neutropenia.